AcelRx Pharmaceuticals, Inc. (ACRX)

NASDAQ: ACRX · IEX Real-Time Price · USD
0.763
-0.062 (-7.49%)
At close: Dec 7, 2023, 4:00 PM
0.795
+0.032 (4.17%)
After-hours: Dec 7, 2023, 5:07 PM EST
-7.49%
Market Cap 13.99M
Revenue (ttm) 622,000
Net Income (ttm) -26.48M
Shares Out 16.95M
EPS (ttm) -2.97
PE Ratio n/a
Forward PE 1.06
Dividend n/a
Ex-Dividend Date n/a
Volume 123,434
Open 0.820
Previous Close 0.825
Day's Range 0.751 - 0.821
52-Week Range 0.430 - 2.780
Beta 0.64
Analysts Strong Buy
Price Target 4.63 (+506.66%)
Earnings Date Nov 8, 2023

About ACRX

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for ... [Read more]

Sector Healthcare
IPO Date Feb 14, 2011
Employees 19
Stock Exchange NASDAQ
Ticker Symbol ACRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ACRX stock is "Strong Buy." The 12-month stock price forecast is $4.63, which is an increase of 506.66% from the latest price.

Price Target
$4.63
(506.66% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topline data expected mid-2024 Cash ...

4 weeks ago - PRNewsWire

AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study

Two KOLs will discuss recent quantitative market research on the use of anticoagulants in the dialysis circuit Discussion will also focus on the Niyad study protocol for upcoming NEPHRO Study Register...

4 weeks ago - PRNewsWire

AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023

HAYWARD, Calif. , Oct. 26, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative...

6 weeks ago - PRNewsWire

AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) allows AcelRx to begin pivotal study of Niyad™ Single registration study with pre-agreed upon endpoints p...

2 months ago - PRNewsWire

AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference

SAN MATEO, Calif. , Sept. 6, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovati...

3 months ago - PRNewsWire

AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits response to Emergency Use Authori...

4 months ago - PRNewsWire

AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

HAYWARD, Calif. , July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative...

4 months ago - PRNewsWire

AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules

Transformative capital raise, led by new investors including Nantahala Capital Management   The private placement provides access to up to $26.3 million of gross proceeds upon the exercise of the mile...

4 months ago - PRNewsWire

AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Upon the achievement of certain milestones accelerating the warrants' expiration date, AcelRx may receive an additional $16.3 million of gross proceeds if the common warrants are exercised in full HAY...

5 months ago - PRNewsWire

AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Request for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 2023 $13.4 million in cash as of March 31, 2023 Webcast a...

7 months ago - PRNewsWire

AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023

HAYWARD, Calif. , April 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...

8 months ago - PRNewsWire

AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals

In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant AcelRx announces full repayment of its senior loan with Oxford Finance HAYWARD, Calif. ,...

8 months ago - PRNewsWire

AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update

Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA Breakthrough designation in line with a s...

9 months ago - PRNewsWire

AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023

HAYWARD, Calif. , March 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...

9 months ago - PRNewsWire

AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals

Agreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up to $116.5 million in potential sales-based milestone...

9 months ago - PRNewsWire

AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures

Study is the first to report on the use of DSUVIA® in the rapidly growing field of rhinology where otolaryngologists are performing painful nasal and sinus procedures in the office which were historic...

10 months ago - PRNewsWire

AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock

HAYWARD, Calif. , Dec. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative ...

1 year ago - PRNewsWire

Three Healthcare Penny Stocks to Watch In The New Year

These three penny (and nickel) stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching.

Other symbols: SLNO
1 year ago - MarketBeat

AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine

Patients reported lower pain scores, required fewer rescue doses and had a shorter hospital stay than patients receiving continuous femoral nerve block This study of patients following knee replacemen...

1 year ago - PRNewsWire

AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Initial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization submission DSUVIA sales of $0.5M in the third quarter, a 217% increase over prior year $...

1 year ago - PRNewsWire

AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022

HAYWARD, Calif. , Nov. 3, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx),  a specialty pharmaceutical company, today announced that it will release third quarter financial ...

1 year ago - PRNewsWire

AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022

The study of 324 complex plastic surgery procedures demonstrated many benefits of using DSUVIA for analgesia, including avoiding the need for general anesthesia HAYWARD, Calif. , Oct. 31, 2022 /PRNews...

1 year ago - PRNewsWire

AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant

Physicians across Europe will now have access to DZUVEO®, a novel sublingual approach to acute pain management in medically supervised settings HAYWARD, Calif. , Oct. 27, 2022 /PRNewswire/ -- AcelRx P...

1 year ago - PRNewsWire

AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022

Brigham and Women's Hospital study found that SST-treated patients had significantly lower pain scores in the post-operative care unit (PACU) compared with patients in the two intravenous opioid contr...

1 year ago - PRNewsWire

AcelRx Pharmaceuticals Announces Reverse Stock Split

HAYWARD, Calif. , Oct. 25, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative...

1 year ago - PRNewsWire